Enzolytics, Inc. (ENZC)
0.0005
0.00 (0.00%)
USD |
OTCM |
Jan 20, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.219M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -47.37% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -0.0084 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.98% |
Profile
| Enzolytics, Inc. is a biotechnology company, which engages in the development and commercialization of drugs for infectious disease treatments. The company’s all-human monoclonal antibodies target and neutralize human immunodeficiency virus and are being employed to produce anti-SARS-CoV-2 monoclonal antibodies for treating COVID-19. Its proprietary therapeutic is also being tested against Hepatitis A, B and C, Rheumatoid Arthritis, certain forms of cancer, rabies, influenza A and B, tetanus, and diphtheria. The company was founded on July 28, 2004 and is headquartered in Allen, TX. |
| URL | http://www.enzolytics.com |
| Investor Relations URL | N/A |
| HQ State/Province | Texas |
| Sector | |
| Industry | |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Enzolytics, Inc. is a biotechnology company, which engages in the development and commercialization of drugs for infectious disease treatments. The company’s all-human monoclonal antibodies target and neutralize human immunodeficiency virus and are being employed to produce anti-SARS-CoV-2 monoclonal antibodies for treating COVID-19. Its proprietary therapeutic is also being tested against Hepatitis A, B and C, Rheumatoid Arthritis, certain forms of cancer, rabies, influenza A and B, tetanus, and diphtheria. The company was founded on July 28, 2004 and is headquartered in Allen, TX. |
| URL | http://www.enzolytics.com |
| Investor Relations URL | N/A |
| HQ State/Province | Texas |
| Sector | |
| Industry | |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |